Clinical Trial Update: Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nivolumab in combination with daratumumab, with or without low-dose cyclophosphamide, for multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Daratumumab (daratumumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Myeloma | Phase 2 | Status: COMPLETED